Neoadjuvant sequential epirubicin and docetaxel followed by surgery-radiotherapy and post-operative docetaxel or gemcitabine/vinorelbine combination based on primary response: a multimodality approach for locally advanced breast cancer.
BACKGROUND
Locally advanced breast cancer (LABC) remains a major clinical issue despite progress achieved in recent years. Herein, we present the mature results of a multimodality treatment program tailoring epirubicin (EPI), docetaxel (DOC) and gemcitabine-vinorelbine (GEV) peri-operatively in LABC.


METHODS
Stage III, Eastern Cooperative Oncology Group-Performance status ≤2 patients were eligible. A biopsy documentation had to be performed before the start of chemotherapy (CT). Treatment consisted of four EPI (100 mg/m(2), d1q2w) followed by three DOC (100 mg/m(2), d1q3w); surgery 3-4 weeks from CT completion, followed by radiation therapy (RT) and CT according to response; partial or complete (PR/CR):DOC, no change or progressive disease (NC/PD):GEV. Primary endpoints were: (a) response and conversion to operability/conservative surgery and (b) overall survival (OS) and time to recurrence (TTR).


RESULTS
Fifty-six women, aged 32-75 (median 52 years), 24 IIIA and 32 IIIB were enrolled; 53 patients completed the entire program. Toxicity was acceptable and no treatment-related death was observed.


RESULTS
clinical response rate (RR) 71.4% (40 patients); clinical complete response rate 33.9% (19 patients). Pathological response rate (RR) 67.8% (38 patients); pathological complete response rate 21.4% (12 patients). 33 (58.9%) and 19 (33.9%) patients, respectively, had radical and conservative operations without increased morbidity. After a median follow-up of 62 months, median OS has not yet been reached, while median TTR was 42 months. OS was longer in patients with clinical (p = 0.004) and pathological response (p = 0.002), RT (p < 0.0001) and post-operative DOC (p = 0.038). TTR was favorably affected by pR (p < 0.0001), RT (p < 0.0004) and post-operative DOC (p = 0.005). Pre-operative CT seemed to be equally active throughout all subgroups according to histology, ER/PR and HER2 status.


CONCLUSIONS
The treatment program of the present study allowed for the completion of an effective therapy at the cost of acceptable toxicity. The results of this study suggest a central role of CT for LABC and the value of eventually dose-dense, EPI- and DOC-based CT in a large proportion of LABC patients, regardless of biological tumor profile. Furthermore, tumor response (cR, pR) is an important surrogate for patients survival and further therapy management.
Kountourakis
Panteleimon
P
First Department of Medical Oncology, St. Savas Anticancer Hospital, 171 Alexandras' Avenue, 11522 Athens, Greece. pantkount@gmail.com
Missitzis
Ioannis
I
Doufexis
Dimitrios
D
Zobolas
Vassileios
V
Pissakas
Georgios
G
Arnogiannaki
Niki
N
Maliou
Savoula
S
Sotiropoulou
Anastasia
A
Ardavanis
Alexandros
A
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D000077143:Docetaxel; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008408:Mastectomy / Q000379:methods; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods*; D018579:Patient Selection; D018714:Radiotherapy, Adjuvant; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D000077235:Vinorelbine; D000093542:Gemcitabine
D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D015251:Epirubicin; D014747:Vinblastine; D000077235:Vinorelbine; D000093542:Gemcitabine
Anticancer Res. 2007 Jul-Aug;27(4C):2989-92
17695483
J Clin Oncol. 1999 Feb;17(2):460-9
10080586
J Clin Oncol. 2006 Mar 1;24(7):1037-44
16505422
J Clin Oncol. 1993 Jul;11(7):1245-52
8315421
J Clin Oncol. 1998 Aug;16(8):2672-85
9704717
J Clin Oncol. 1992 Jun;10(6):1014-24
1588366
Ann Oncol. 2003 Mar;14(3):406-13
12598346
J Clin Oncol. 2006 May 1;24(13):2019-27
16606972
Breast Cancer Res Treat. 2005 Apr;90(3):215-21
15830134
Oncologist. 2006 Jun;11(6):563-73
16794236
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
10655437
J Clin Oncol. 2008 Feb 10;26(5):778-85
18258986
J Clin Oncol. 2002 Sep 1;20(17):3628-36
12202663
J Clin Oncol. 2004 Oct 15;22(20):4067-74
15483018
J Clin Oncol. 1995 Nov;13(11):2722-30
7595730
J Clin Oncol. 2002 Mar 15;20(6):1456-66
11896092
J Clin Oncol. 2005 Apr 20;23(12):2676-85
15837982
J Clin Oncol. 2010 Jan 1;28(1):83-91
19901111
Oncologist. 2003;8(6):521-30
14657530
Cancer Chemother Pharmacol. 2003 Aug;52(2):147-52
12764672